Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Females Age 9 To 15 Years~* Females Not Sexually Active And Not Plan On Becoming Sexually Active During The Study~* No Fevers 24 Hours Prior To The First Injection~Exclusion Criteria:~* Participant Had Received A Prior Vaccination With A HPV Vaccine~* Participant Has Allergies To Vaccine Component Including Aluminum And Yeast~* Participant Has (Human Immunodeficiency Virus) HIV Infection~* Participant Is Immunocompromised~* Participant Received Or Plans To Receive Blood-Derived Product Within 6 Months Prior To The First Injection~* Participant Received Or Plans To Receive Immune Globulin Preparation Within 6 Months To The First Injection

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18) (Type: EXPERIMENTAL): Participants who enroll receive a total of 3 intramuscular injections of Quadrivalent HPV VLP vaccine (types 6, 11, 16, 18) given on Day 1, Month 2 and Month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).